Grazoprevir
FDA-approved product (tablet, oral).
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Chronic hepatitis C virus infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Antivirals for treatment of hcv infections
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP11
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA61.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae44.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Grazoprevir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Lumateperone TosylateExisting use: Psychosis, Schizophrenia65.8% AI-predicted activityagainst M. tuberculosis6 registered studies
- Moexipril HydrochlorideExisting use: Cardiovascular disease, Hypertension65.8% AI-predicted activityagainst M. tuberculosis12 registered studies
- VismodegibExisting use: Basal cell carcinoma, Cancer, Neoplasm and 1 more65.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- DarunavirExisting use: HIV infection, HIV-1 infection, Immunodeficiency disease and 2 more65.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Lenacapavir SodiumExisting use: HIV infection, HIV-1 infection, Viral disease65.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- LisinoprilExisting use: Cardiovascular disease, Congestive heart failure, Diabetes mellitus and 4 more65.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Umbralisib TosylateExisting use: Follicular lymphoma, Marginal zone B-cell lymphoma, Neoplasm65.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- BrigatinibExisting use: Neoplasm, Non-small cell lung carcinoma65.4% AI-predicted activityagainst M. tuberculosis48 registered studies
- GlyburideExisting use: Diabetes mellitus, Type 2 diabetes mellitus65.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ThiothixeneExisting use: Psychosis, Schizophrenia65.4% AI-predicted activityagainst M. tuberculosis5 registered studies
- GefitinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma65.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- PimozideExisting use: Psychosis, Tics, Tourette syndrome65.2% AI-predicted activityagainst M. tuberculosis15 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
NCT01717326 · start 2013-02-07
Registered record
- Registry ID
- NCT01717326
- Conditions
- Hepatitis C
- Interventions
- Grazoprevir; Elbasvir; Placebo to Elbasvir; Ribavirin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2013-02-07
- Completion
- 2015-05-06
- Enrolment
- 573
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatitis CInterventionGrazoprevir; Elbasvir; Placebo to Elbasvir; RibavirinPhasePhase 2Registry statusCompletedA Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039)
NCT01716156 · start 2013-01-18
Registered record
- Registry ID
- NCT01716156
- Conditions
- Hepatitis C
- Interventions
- Grazoprevir; Ribavirin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2013-01-18
- Completion
- 2014-03-12
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatitis CInterventionGrazoprevir; RibavirinPhasePhase 2Registry statusCompletedA Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)
NCT01710501 · start 2012-12-07
Registered record
- Registry ID
- NCT01710501
- Conditions
- Chronic Hepatitis C (CHC)
- Interventions
- Grazoprevir; pegylated interferon alfa-2b; Ribavirin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2012-12-07
- Completion
- 2014-01-29
- Enrolment
- 87
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Hepatitis C (CHC)InterventionGrazoprevir; pegylated interferon alfa-2b; Ribavirin; PlaceboPhasePhase 2Registry statusCompletedEvaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)
NCT01547312 · start 2012-05
Registered record
- Registry ID
- NCT01547312
- Conditions
- Chronic Hepatitis C
- Interventions
- Peg-Interferon; Liver Samples from FNA; Liver Samples from CNB; Blood Samples; Ribavirin; 800 mg Grazoprevir; 100 mg Grazoprevir; Liver samples from CNB and FNA
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Withdrawn
- Start
- 2012-05
- Completion
- 2012-11
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Hepatitis CInterventionPeg-Interferon; Liver Samples from FNA; Liver Samples from CNB; Blood Samples +4 morePhasePhase 1Registry statusWithdrawnA Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)
NCT00998985 · start 2010-02-23
Registered record
- Registry ID
- NCT00998985
- Conditions
- Hepatitis C
- Interventions
- Grazoprevir; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-02-23
- Completion
- 2012-11-08
- Enrolment
- 91
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatitis CInterventionGrazoprevir; PlaceboPhasePhase 1Registry statusCompleted